2021
DOI: 10.3390/s21227477
|View full text |Cite
|
Sign up to set email alerts
|

Bioprinting of Stem Cells in Multimaterial Scaffolds and Their Applications in Bone Tissue Engineering

Abstract: Bioprinting stem cells into three-dimensional (3D) scaffolds has emerged as a new avenue for regenerative medicine, bone tissue engineering, and biosensor manufacturing in recent years. Mesenchymal stem cells, such as adipose-derived and bone-marrow-derived stem cells, are capable of multipotent differentiation in a 3D culture. The use of different printing methods results in varying effects on the bioprinted stem cells with the appearance of no general adverse effects. Specifically, extrusion, inkjet, and las… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
15
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 30 publications
(15 citation statements)
references
References 124 publications
0
15
0
Order By: Relevance
“…MSC isolated from a variety of tissues have been isolated and then often incorporated into synthetic scaffolds, scaffolds with other ECM-like matrix components, an endogenous natural protein matrix or a hybrid synthetic/natural matrix, reviewed in [ 156 , 157 , 158 , 159 ]. Recent advances in bioprinting may offer more sophisticated and complex scaffold-cell constructs [ 160 , 161 , 162 ]. Such constructs are then implanted into defects in tissues or in an injury site.…”
Section: Use Of Msc In Tissue Engineered Constructs To Enhance Repair...mentioning
confidence: 99%
“…MSC isolated from a variety of tissues have been isolated and then often incorporated into synthetic scaffolds, scaffolds with other ECM-like matrix components, an endogenous natural protein matrix or a hybrid synthetic/natural matrix, reviewed in [ 156 , 157 , 158 , 159 ]. Recent advances in bioprinting may offer more sophisticated and complex scaffold-cell constructs [ 160 , 161 , 162 ]. Such constructs are then implanted into defects in tissues or in an injury site.…”
Section: Use Of Msc In Tissue Engineered Constructs To Enhance Repair...mentioning
confidence: 99%
“…Generally, higher viscous bioinks extruded from nozzles results in higher shear-stress, which is detrimental to cell viabilities. Additionally, the printing resolution is limited, with the range between 200 and 1000 ”m, compared with other technologies [ 64 ].…”
Section: D Printing Technologies For Hard Tissue Replacementmentioning
confidence: 99%
“…Cells, growth factors, and scaffolds are a necessary triad for tissue engineering. Despite advances in scaffold development and the identification of new growth factors and their genetic manipulation [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ], delivering sufficient numbers of cells and maintaining them in areas of interest, regardless of whether for ex vivo tissue engineering or in situ regeneration, has been challenging [ 1 , 12 , 15 , 16 , 17 , 18 , 19 , 20 ]. The effective delivery of stem cells or osteogenic cells derived from bone marrow or other source organs has been investigated in the context of tissue engineering and regeneration [ 12 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ].…”
Section: Introductionmentioning
confidence: 99%
“…The effective delivery of stem cells or osteogenic cells derived from bone marrow or other source organs has been investigated in the context of tissue engineering and regeneration [ 12 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ]. Various methods to improve cellular delivery have also been examined, including cell sheet technology, injectable vehicles, carrier molecules, and 3-dimensional (3D) cell printing [ 2 , 27 , 29 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ]. Despite some progress, cell-based repair and regeneration of tissues, particularly fractured and diseased bone remains far from being a standard clinical modality, with the approach hampered by poor clinical viability, high costs, and suboptimal biological efficacy [ 37 , 38 , 47 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ].…”
Section: Introductionmentioning
confidence: 99%